MedTrace Logo

LY3214996 +/- HCQ in Pancreatic Cancer

NCT04386057 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-02-12

Study results available
· View outcomes & findings →

Summary

This study is evaluating the safety and efficacy of combining the study drug LY3214996 with hydroxychloroquine sulfate (HCQ) in patients with advanced pancreatic cancer.

Conditions

Interventions

DRUG

Hydroxychloroquine Sulfate

HCQ will be administered by mouth twice daily continuously throughout each treatment per 28 day cycle

DRUG

LY3214996

LY3214996-daily oral dosage per protocol per 28 day cycle

Sponsors & Collaborators

Principal Investigators

  • Kimberly Perez, MD · Dana-Farber Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-27
Primary Completion
2023-08-09
Completion
2024-02-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04386057 on ClinicalTrials.gov